The PE Ratio as of November 2024 (TTM) for Codexis, Inc. (CDXS) is -5.24

According to Codexis, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.24. This represents a change of 18.65% compared to the average of -4.42 of the last 4 quarters.

Codexis, Inc. (CDXS) Historical PE Ratio (quarterly & annually)

How has CDXS PE Ratio performed in the past?

The mean historical PE Ratio of Codexis, Inc. over the last ten years is -38.22. The current -5.24 PE Ratio has changed 1.27% with respect to the historical average. Over the past ten years (40 quarters), CDXS's PE Ratio was at its highest in in the September 2019 quarter at 582.87. The PE Ratio was at its lowest in in the December 2018 quarter at -488.80.

Codexis, Inc. (CDXS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Codexis, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Codexis, Inc. (CDXS) Average PE Ratio

How has CDXS PE Ratio performed in the past?

The current PE Ratio of Codexis, Inc. (CDXS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Codexis, Inc. (CDXS) PE Ratio vs. Peers

How is CDXS’s PE Ratio compared to its peers?

Codexis, Inc.’s PE Ratio is less than Nuvation Bio Inc. (-1.44), less than Lyell Immunopharma, Inc. (-1.19), less than Century Therapeutics, Inc. (-0.79), less than Generation Bio Co. (-0.63), less than Shattuck Labs, Inc. (-0.69), greater than Foghorn Therapeutics Inc. (-5.38), greater than Monte Rosa Therapeutics, Inc. (-5.83), greater than Kymera Therapeutics, Inc. (-20.45), greater than Nurix Therapeutics, Inc. (-9.07), greater than Kezar Life Sciences, Inc. (-5.71), less than Mineralys Therapeutics, Inc. (-4.06), less than Nkarta, Inc. (-1.63), less than NGM Biopharmaceuticals, Inc. (-1.35), less than Cullinan Oncology, Inc. (-5.10), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Revolution Medicines, Inc. (-16.70),

Build a custom stock screener for Codexis, Inc. (CDXS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Codexis, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Codexis, Inc. (CDXS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Codexis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.